The therapeutic efficacy of anti-CTLA-4 immunotherapy against intracranial gliomas requires a distal B-cell and antibody response initiated inside the tumor-draining deep cervical lymph nodes.
The therapeutic efficacy of anti-CTLA-4 immunotherapy against intracranial gliomas requires a distal B-cell and antibody response initiated inside the tumor-draining deep cervical lymph nodes.